Retrospective Brazilian Study of Fulvestrant in Advanced Breast Cancer

• Status: Completed
• Trial end date: 2009-04-01
• Target enrollment: 0
• Participant gender: Female

Summary

Characterize the demographic and clinical features, as well as the main treatment results, among patients with advanced breast cancer treated with fulvestrant in Brazil.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AstraZeneca
• Collaborator: Dendrix - Scientific Information Architecture
• Treatments: Estradiol; Fulvestrant

Criteria

Inclusion Criteria:

• Positive HR or ER by immunohistochemistry

• Postmenopausal status at the time of treatment with fulvestrant

• Failure of at least one previous endocrine therapy before treatment with fulvestrant.

Exclusion Criteria:

• Patients who are still undergoing treatment with fulvestrant will not be eligible to participate in the study